《Rapid Information on OLM No 220 140608》由会员分享，可在线阅读，更多相关《Rapid Information on OLM No 220 140608（5页珍藏版）》请在金锄头文库上搜索。
1、Rapid Information on Olmesartan and other ARBsNo.220 2014/06/08 Be the first to know! (Toru Komai, Ph.D.)220-1: The combination of olmesartan with azelnidipine is more beneficial with regard to BP control and metabolic outcome than the combination of olmesartan with low dose trichlormethiazide in hy
2、pertensive patients with diabetes mellitus.Title：Comparison of effects of azelnidipine and trichlormethiazide in combination with olmesartan on blood pressure and metabolic parameters in hypertensive type 2 diabetic patients. 2220-2: A small but significantly increased diabetes incidence was found i
3、n olmesartan initiators as compared to losartan initiators in a large nationwide population-based cohort in Taiwan.Title：Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study. 3-4220-3: A case report: Olmesartan-induced enteropathy resembling c
4、eliac disease.Title：Olmesartan-induced enteropathy resembling celiac disease. 4220-4: Overall, 54 patients, equally distributed between men and women, have developed a sprue-like enteropathy associated with olmesartan treatment for arterial hypertension: A systematic review.Title：Systematic review:
5、sprue-like enteropathy associated with olmesartan. 5Abbreviations: BP: blood pressure, SBP/DBP: systolic/ diastolic BP, RAS: reninangiotensin system, Ang II: angiotensin II, ARB: angiotensin II receptor blocker, CCB: calcium channel blocker, ACE-inhibiyor: angiotensin converting enzyme inhibitor, HR
6、: hazard ratio, OR: odds ratio,220-1: The combination of olmesartan with azelnidipine is more beneficial with regard to BP control and metabolic outcome than the combination of olmesartan with low dose trichlormethiazide in hypertensive patients with diabetes mellitus.The recent ACCOMPLISH trial sho
7、wed that the combination of CCB with ACE inhibitors is more effective in reducing cardiovascular events compared to the combination of thiazide diuretics with ACE inhibitors in high-risk hypertensive patients. However, the effects of ARB combined with CCB or thiazide diuretics have not been fully ev
8、aluated in type 2 diabetic patients with hypertension.In this open-label, prospective, crossover clinical trial, the authors compared the effects of combination treatment of ARB (olmesartan) with a CCB (azelnidipine) or with a low-dose thiazide diuretic (trichlormethiazide) on BP and various metabol
9、ic parameters in hypertensive patients with type 2 diabetes. A total of 39 Japanese type 2 diabetics with hypertension treated with olmesartan (20mg/day) for at least 8 weeks were recruited to this study. At study entry, treatment was switched to either olmesartan (20mg/day)/azelnidipine (16mg/day)
10、or olmesartan (20mg/day)/trichlormethiazide (1mg/day) and continued for 12weeks. Then, the drugs were switched and treatment was continued for another 12weeks. As results, compared with the combination of olmesartan and trichlormethiazide, that of olmesartan and azelnidipine had superior BP lowering
11、 effects, as well as superior effects on glucose and uric metabolism, and renal function in patients with type 2 diabetes. The treatment with olmesartan/trichlormethiazide resulted in increased HbA1c, serum uric acid and worsening of estimated glomerular filtration rate. There were no differences in
12、 other metabolic parameters including urine 8-hydroxy-2-deoxyguanosine, C-reactive protein and adiponectin between the two treatments. (RIO14-050)(Although this paper was published in 2011, it was recently included in PubMed.)TitleComparison of effects of azelnidipine and trichlormethiazide in combi
13、nation with olmesartan on blood pressure and metabolic parameters in hypertensive type2 diabetic patients.JournalJ Diabetes Investig. 2011 Nov 30;2(6):490-6. Free articleAuthorYoshii H, Mita T, Sato J, Kodama Y, Choi JB, Komiya K, Matsumoto K, Kanno R, Kawasumi M, Koyano H, Hirose T, Onuma T, Kawamo
14、ri R, Watada HFacilityDepartment of Medicine, Diabetes and Endocrinology, Juntendo Tokyo Koto Geriatric Medical Center.Date2014/06/08 PMID:24843534220-2: A small but significantly increased diabetes incidence was found in olmesartan initiators as compared to losartan initiators in a large nationwide
15、 population-based cohort in Taiwan.The anti-diabetic action of ARBs appears to be complex, including activation of peroxisome proliferator-activated receptor- (PPAR), suppression of oxidative stress, inhibition of fibrosis, and enhancement of insulin signalling. There is substantial difference in the chemical structure and lipid solubility among ARBs. Thus, for instance, different ARBs had different degrees of PPAR agonist activities. Te
